Alector, Inc. (ALEC) Discusses On Alector R&D Briefing: A Review Of Our PGRN Franchise And Brain Carrier Programs Transcript

Discover Alector's latest breakthroughs in neurodegenerative disease therapies, including updates on Alzheimer's and Parkinson's programs.

Ascletis Pharma Inc.: Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity ...

The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide ...

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to ...
eLife

Ptbp1 is not required for retinal neurogenesis and cell fate specification

Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, United States ...